The healthcare industry continues to enjoy immense investor attention, thanks partly to the resurgence of COVID-19 cases and the identification and effects of new variants of the deadly virus. Investors’ interest in the healthcare stocks is…
evident in the Health Care Select Sector SPDR Fund’s (XLV) 9.5% returns over the past three months.
Also, an aging population and relatively inelastic demand for healthcare products and services are expected to boost the industry’s growth. Total U.S. healthcare spending is expected to be $10.43 trillion this year.
Wall Street analysts expect small-cap healthcare stocks BeyondSpring Inc. (BYSI – Get Rating) and SCYNEXIS, Inc. (SCYX – Get Rating) to rally significantly in the near term. So, we think it could be wise to add the stocks to one’s watch list.
BYSI is a clinical-stage biopharmaceutical company in New York City that develops innovative immuno-oncology cancer therapies. It has a market capitalization of $1.08 billion. Also, its lead asset, plinabulin, is in two phase 3 global clinical trials as a direct anticancer agent in treating non-small cell lung cancer (NSCLC) and preventing chemotherapy-induced neutropenia (CIN).
On August 26, 2021, BYSI formed an exclusive commercial collaboration with China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. to produce plinabulin. This is expected to help increase the company’s revenue in the near term.
BYSI’s total revenue came in at $338,000 for its fiscal first quarter, ended March 31, 2021. Its net loss was $16.08 million, versus $16.99 in the year-ago period. Also, its loss per share was $0.44 compared to $0.58 in the prior-year period. However, its total liabilities decreased 14.6% sequentially to $21.53 million.
For its fiscal year 2022, analysts expect BYSI’s revenue to be $105.49 million, representing a 20,998% year-over-year rise. The company’s EPS is expected to increase 75.8% year-over-year in fiscal 2022. In addition, it surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past month, the stock has gained 189.8% in price to close yesterday’s trading session at $27.59. Wall Street analysts expect the stock to hit $97.50 in the near term, which indicates a potential 253.45 upside.
With a market capitalization of $147.43 million, SCYX is a biotechnology company delivering fungal infections treatment. Its lead product, ibrexafungerp, is being formalized as a novel oral and intravenous drug to treat various fungal infections. SCYX is based in Jersey City, N.J.
SCYX announced on June 2, 2021, that the U.S. FDA had…
Continue reading at STOCKNEWS.com